Stock DNA
Pharmaceuticals & Biotechnology
SEK 17,808 Million (Small Cap)
59.00
NA
0.06%
1.68
12.96%
3.17
Revenue and Profits:
Net Sales:
6,539 Million
(Quarterly Results - Jun 2025)
Net Profit:
197 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.32%
0%
-11.32%
6 Months
-3.95%
0%
-3.95%
1 Year
27.62%
0%
27.62%
2 Years
61.31%
0%
61.31%
3 Years
66.91%
0%
66.91%
4 Years
-17.5%
0%
-17.5%
5 Years
67.39%
0%
67.39%
Medicover AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
21.47%
EBIT Growth (5y)
29.36%
EBIT to Interest (avg)
3.30
Debt to EBITDA (avg)
1.57
Net Debt to Equity (avg)
1.35
Sales to Capital Employed (avg)
1.64
Tax Ratio
28.27%
Dividend Payout Ratio
129.11%
Pledged Shares
0
Institutional Holding
0.18%
ROCE (avg)
11.54%
ROE (avg)
9.18%
Valuation key factors
Factor
Value
P/E Ratio
59
Industry P/E
Price to Book Value
7.38
EV to EBIT
33.60
EV to EBITDA
12.22
EV to Capital Employed
3.25
EV to Sales
1.89
PEG Ratio
0.39
Dividend Yield
0.03%
ROCE (Latest)
9.68%
ROE (Latest)
12.45%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Jun 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.18%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
6,539.00
5,862.10
11.55%
Operating Profit (PBDIT) excl Other Income
1,066.30
821.70
29.77%
Interest
180.80
162.30
11.40%
Exceptional Items
-12.10
-9.20
-31.52%
Consolidate Net Profit
197.30
67.90
190.57%
Operating Profit Margin (Excl OI)
71.70%
43.40%
2.83%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 11.55% vs 20.31% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 190.57% vs -17.80% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
23,922.70
20,043.50
19.35%
Operating Profit (PBDIT) excl Other Income
3,291.40
2,810.70
17.10%
Interest
672.50
589.90
14.00%
Exceptional Items
-220.70
-10.30
-2,042.72%
Consolidate Net Profit
167.00
211.20
-20.93%
Operating Profit Margin (Excl OI)
42.80%
35.70%
0.71%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 19.35% vs 24.79% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -20.93% vs 44.96% in Dec 2023
About Medicover AB 
Medicover AB
Pharmaceuticals & Biotechnology
Medicover AB is a Sweden-based healthcare and diagnostic services provider. It offers a broad range of healthcare services and hub-and-spoke diagnostic laboratory network, supported by proprietary software and information systems infrastructure. The Company offers its services through two divisions: Healthcare Services and Diagnostic Services. The Healthcare Services division offers services ranging from primary care to specialist outpatient and inpatient care. The care is delivered mainly through Medicover’s own network of clinics and medical facilities. The Diagnostic Services division offers a broad range of diagnostic laboratory testing for humans and some veterinary services across all main clinical pathology specialties. The Company focuses primarily on such markets, as Poland, Germany, Romania, Ukraine.
Company Coordinates 
Company Details
Riddargatan 12 3Tr , STOCKHOLM None : 114 35
Registrar Details






